NEW YORK (GenomeWeb News) – Merck KGaA's agreement to acquire Millipore has cleared US anti-trust review, Millipore said in a filing today with the US Securities and Exchange Commission.
The firms agreed to the deal at the end of February. Under terms of the deal, Darmstadt, Germany's Merck will pay $107 per share for all of Millipore's stock for a total transaction value of roughly $7.2 billion. The deal values Millipore at 4.4 times its 2009 sales of $1.65 billion.
Millipore said in its SEC filing that the waiting period for a review by the US Department of Justice and the Federal Trade Commission had expired without a request for any additional information.
In early Wednesday afternoon trade on the New York Stock Exchange, shares of Millipore were up less than 1 percent at $106.22 per share.